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1. Introduction 
 
1.1 Overview 
 
Traditionally, the nervous and immune systems have been regarded to function largely 
independently of each other. Evidence accumulated during the past two decades, however, 
has demonstrated the bidirectional communications between the central nervous system 
(CNS) and the immune system. 
 
The first sustained program of research on brain-immune system interactions began in 
the 1920s and concerned the Pavlovian conditioning of ‘immune’ reactions. In the 1950s, 
there was a short-lived, but later received, interest in the immunologic effects of lesioning 
and electrical stimulation of the hypothelamus. At the same time, Fred Rasmussen, Jr., a 
virologist, and Norma Brill, a psychiatrist, initiated studies on the effects of stressful life 
experiences on susceptibility to experimentally induced infectious diseases (Ader et al., 
2001). 
 
Interest in this interdisciplinary research was rejuvenated when, in the 1970s, several 
independent lines of research converged to provide verifiable evidence of interactions 
between the brain and the immune system. John Hadden linked the immune system to the 
sympathetic nervous system (SNS) by documenting the existence of β-adrenergic 
receptors (ARs) on lymphocytes (Hadden et al., 1970); Robert Ader and Nicholas Cohen 
demonstrated behaviorally conditioned suppression of the immune system, providing a 
functional link between the brain and the immune system (Ader and Cohen, 1975); Roger 
Bartrop and his associates described immunologic changes associated with the 
bereavement that following the death of a spouse (Bartrop et al., 1977); Hugo Besedovsky 
began to piece together a neuroendocrine-immune system network with his studies of the 
effects of immune responses on neural and endocrine functions (Besedovsky et al., 1983); 
the sympathetic innervation of lymphoid tissues was documented by David and Suzanne 
Felten (Felten et al., 1987a; Felten and Olschowka, 1987) and connections to the thymus 
were documented by Karen Bulloch (Bulloch and Pomerantz, 1984); and Edwin Blalock 
and Eric Smith showed that lymphocytes, themselves, were capable of producing 
neuropeptides (Blalock and Smith, 1980). These seminal studies precipitated new research 
on the receptors for hormones and neurotransmitters that existed on lymphocytes, the 
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effects of SNS activity on immunity, conditioned immune responses, depression and 
immunity, the influence of stressful life experiences on immune function and resistance to 
disease, psychosocial factors in the progression of acquired immunodeficiency syndrome 
(AIDS), and immunologic effects on behavior (Ader et al., 2001). Thus, we have 
witnessed an explosive growth of a new research area that studies neuroimmune 
communication in the last two dacades. 
 
1.2 Occurrence and regional distribution of catecholamines in the central nervous 
system 
 
The CNS contains three types of catecholamines: norepinephrine (NE), dopamine (DA), 
and epinephrine (EPI) (Moore and Bloom, 1978). Biochemical measurement of 
transmitter levels in extracts of microdissected brain nuclei has helped clarify the 
distribution of them in the CNS. In table 1 the concentrations of NE, DA and EPI in 
several regions of rat brain are reported (Müller and Nisticò, 1989a). 
 
The distinct neuronal groups in the brain stem are the major souce of catecholaminergic 
input to most parts of the brain. Histochemical techniques revealed three major 
catecholaminergic cell groups in the brain stem. These groups are distinguished by their 
transmitters: NE, DA and EPI (Role and Kelly, 1991). 
 
Two principal nuclei in the brain stem contain noradrenergic neurons. These are (1) the 
locus ceruleus, located in the rostral pontine central gray region, and (2) the lateral 
tegmental neurons, which are more scattered in the medullary lateral pontine tegmentum. 
The neurons of the locus ceruleus have both descending and ascending axonal branches. 
The descending branches go to the spinal cord (predominantly to the ventral horn) and to 
the brain stem itself (primarily to sensory nuclei). Ascending projections terminate in the 
diencephalon (largely in the dorsal thalamus, with a smaller projection terminating in the 
hypothalamus), in the cerebellum, the basal forebrain (including the hippocampus), and 
the neocortex. The locus ceruleus receives only two major inputs. These come from two 
brain stem nuclei: the nucleus paragigantocellularis and the nucleus hypoglossi prepositus. 
Thus, the locus ceruleus receives restricted afferent input yet makes very broad efferent 
projections (Role and Kelly, 1991). 
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Table 1. Concentrations of norepinephrine, dopamine, and epinephrine 
in several nuclei and areas of the rat braina 
 
Site Concentration 
(ng/mg protein) 
Norepinephrine  
Nucleus interstitialis striae terminalis 80.2 
Dorsomedial nucleus 55.1 
Locus coeruleus 53.1 
Paraventricular nucleus 52.9 
Retrochiasmatic area 48.0 
Periventricular nucleus 45.7 
Nucleus tractus solitarii 37.4 
Nucleus interstitialis striae medullaris 33.2 
Medial forebrain bundle 29.8 
Supraoptic nucleus 29.0 
Dopamine  
Olfactory tubercle 104.5 
Nucleus accumbens 87.2 
Caudate-putamen 85.2 
Median eminence 61.5 
Ventral striatum 57.6 
Anterior amygdala area 45.9 
Globus pallidus 39.6 
Nucleus tractus diadonalis 33.9 
Area tegmentalis ventralis 22.4 
Lateral septal nucleus 21.3 
Epinephrine  
Periventricular nucleus 2.52 
Dorsomedial nucleus 2.53 
Nucleus tractus solitarii 2.19 
Paraventricular nucleus 2.16 
Supraoptic nucleus 2.14 
Median eminence 1.83 
Lateral mammillary nucleus 1.51 
Arcuate nucleus 1.41 
Midline thalamic nucleus 1.27 
a From Müller and Nisticò (1989a) 
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The locus ceruleus only contains half of the total number of noradrenergic neurons in 
the brain stem. The rest are distributed diffusely throughout the ventral lateral tegmentum. 
An example of this group is the lateral tegmental neurons. Like the neurons of the locus 
ceruleus, the axons of the lateral tegmental neurons have extensive collaterals and dense 
terminal arborizations. The axons project to three major sites: (1) the spinal cord, (2) the 
brain stem and (3) the thalamus and cerebellar and cerebral cortices (Where the input is 
minor compared to that of the locus ceruleus). In general, neurons of the lateral tegmental 
region do not overlap their targets with those of the locus ceruleus. Thus, whereas the 
neurons of the locus ceruleus provide the principal noradrenergic input to the neocortex, 
the lateral tegmental neurons provide the major noradrenergic input to the brain stem and 
spinal cord. The physiological significance of these divergent noradrenergic projections is 
illustrated by the extensive behavioral effects produced by drugs that alter central NE 
action (Role and Kelly, 1991). 
 
When neurons of the locus ceruleus are activated by novel sensory input, they respond 
as a group with an increased burst of activity. This coordinate response to a change in 
sensory input suggests that these neurons have a role in orienting and attending to sudden 
contrasting, or aversive sensory input. Neurons of the lateral tegmental noradrenergic 
system contribute to the integration of autonomic function in brain stem and spinal cord 
nuclei through projections to sympathetic preganglionic neurons in the intermediolateral 
cell column as well as to the nucleus of the solitary tract and the dorsal tegmental neurons 
leads to a profound decrease in mean arterial pressure, heart rate, and blood pressure (Role 
and Kelly, 1991). 
 
There are about three to four times as many dopaminergic neurons as noradrenergic 
neurons in the brain. In contrast to the diffuse projections of the noradrenergic system, the 
dopaminergic system is highly organized topographically. On the basis of their efferent 
projections, dopaminergic cell groups have been broadly classified into two groups: (1) 
the mesostriatal system, and (2) the mesolimbic and mesocortical systems. The 
mesostriatal system projects from the substantia nigra and the ventral tegmentum to 
several striatal areas. This system plays an important role in the control of voluntary 
movement. Selective destruction or degeneration of the mesostriatal dopaminergic system 
results in the motor disorders of Parkinson’s disease (PD). The mesolimbic and 
mesocortical systems project from the ventral tegmentum to limbic and cortical areas. The 
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function of these projections is not known, but they are thought to participate in cognition. 
The dopaminergic system is also considered the primary site of action of many stimulants 
(e.g. amphetamines) as well as antipsychotic drugs (Björklund and Lindvall, 1984). 
 
Dopaminergic neurons are also found in other regions of the CNS including the 
tuberohypophyseal incertohypothalamic and medullary periventricular neurons, the dorsal 
and ventrolateral preoptic areas, the hypothalamus, the olfactory bulb and the retinal 
dopaminergic neurons (Björklund and Lindvall, 1984). The organization of dopaminergic 
systems in the rat brain is summarized in Table 2 (Müller and Nisticò, 1989a). 
 
The use of an immunohistochemical method has made possible the demonstration in the 
mammalian CNS of neurons containing EPI (Hökfelt et al., 1984). In particular, by means 
of antibodies against phenylethanolamine-N-methyltransferase (PNMT), the enzyme 
converting NE into EPI, it has been clearly demonstrated that certain areas of the brain 
such as the olfactory bulb, olfactory tubercle, and the hypothalamus contain substantial 
amouts of the enzyme and therefore are capable of forming EPI in vivo. The EPI cell 
bodies have been found in the reticular formation of the medulla oblongata; they send 
descending axons to the sympathetic lateral column and ascending axons into the 
hypothalamus, the pericentricular gray, and the locus coeruleus. Furthermore, there is a 
dense EPI innervation of the nucleus dorsalis, nucleus vagi, and the nucleus tractus solitari 
(Hökfelt et al., 1984). The cell bodies of PNMT-immunoreactive neurons in the medulla 
oblongata are organized into two systems, a ventral C1 and a dorsal C2 group. The cells in 
the C1 group appear caudal to the area postrema, dorsolateral and/or ventromedial to the 
reticular nucleus (Müller and Nisticò, 1989a). Generally, PNMT-positive nerve endings 
have a more limited distribution than do those of the other two catecholamines although 
they extend from the forebrain to the spinal cord, mostly concentrated along the 
ventricular system. Telencephalic structures are poorly innervated, whereas a richer 
innervation exists in the diencephalon. In particular, a moderately dense network of 
PNMT-positive fibers is found in the periventricular area, including the suprachiasmatic 
part of the preoptic nucleus and the arcuate nucleus of the hypothalamus. A dense PNMT-
reactive network is observed at the mid-hypothalamic level, in the paraventricular nucleus, 
and in the rostral part of the periventricular region (Müller and Nisticò, 1989a). 
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Table 2. Main dopaminergic pathways and systems in the rat braina 
System Cells of origin Projections 
Mesostriatal Substantia nigra (A9) Caudate-putamen 
 Ventral tegmental area (A10) 
Retrorubral nucleus (A8) 
Ventral striatum (nucleus acc-
umbens), olfactory tubercle, bed 
nucleus, striae terminalis 
  Globus pallidus 
  Island of Galleja 
  Subthalamic nucleus 
Mesolimbocortical Ventral tegmental area (A10) Olfactory bulb 
 Substantia nigra (A9) Anterior septal nucleus 
 Retrorubral nucleus (A8) Piriform cortex 
  Amygdala 
  Ventral entorhinal cortex 
  Suprarhinal cortex 
  Pregenual anteromedial cortex 
  Supragenual anteromedial cortex 
  Perirhinal cortex and temporal 
association cortex 
  Lateral habenular nucleus 
  Locus coeruleus 
Mesothalamic Ventral tegmental area (A10) Thalamus 
Diencephalospinal Dorsal  and  posterior  hypothalamus, 
zona incerta, caudal thalamus (A11) 
Spinal cord 
Intertohypothalamic Zona incerta, periventricular hypo-
thalamic nuclei (A11, A13, A14) 
Zona incerta, anterior medial 
preoptic and periventricular 
hypothalamus, septum 
Tuberoinfundibular and 
tuberohypophyseal 
Arcuate and periventricular hypo-
thalamic nuclei (A12, A14) 
Median eminence 
Pars intermedia and nervosa of 
pituitary 
Periventricular Mesencephalic periqueductal gray 
 Periventricular gray of caudal tha- 
lamus (A11) 
Periqueductal gray 
Medial thalamus and hypotha-
lamus 
Periglomerular Olfactory bulb (A16) Dendritic processes into olfactory 
glomeruli 
Retinal Mainly in amacrine cells of inner 
nuclear layer of retina 
Local dendritic projections 
a From Müller and Nisticò (1989a) 
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1.3 Central catecholamines and immunity 
 
It is well known that the CNS can influence the immune system via various pathways. 
This is primarily achieved by several neurotransmitters, neuropeptides, hormones and 
cytokines which interact with different immune effector cells and thereby ultimately 
regulate the homeostatic response of an individual to disease and other environmental 
stresses (Weigent and Blalock, 1987). Among these neural mediators of homeostasis, 
central catecholamines play a significant role, which has been proved by numerous 
clinical and experimental observations (Basu and Dasgupta, 2000; Kohm and Sanders, 
2000). 
 
1.3.1 Correlation between central catecholamines and immunity in pathophysiolo-
gical conditions 
 
Degeneration of nigrostriatal dopaminergic neurons is the cause of PD, resulting in 
hypodopaminergic activity of the CNS (Temlett, 1996). On the contrary, a 
hyperdopaminergic activity has been emphasized in schizophrenia (Birtwistle and 
Baldwin, 1998). Moreover, considerable evidence has also been accumulated, suggesting 
that both of these neurological disorders involving CNS catecholaminergic system are 
associated with significant alterations in immune response. 
 
Evidence for the abnormalities in immune response in patients with PD appeared in the 
late 1970s, Hoffman et al. (1978) reported that the T-cell numbers and percentages and 
the total number of lymphocytes as well as their ability to respond to mitogenic 
stimulation were reduced in Guamanian patients with PD. Their later study showed that 
higher IgA and lower IgM levels in serum were also found in these patients (Hoffman et 
al., 1981). Following investigations demonstrated that patients with PD had a reduction in 
the proliferative response of peripheral lymphocytes to concanavalin A (Con A), 
phytohaemagglutinin (PHA) and pokeweed mitogen (PWM) and a decrease in antibody 
production (Marttila et al., 1985). Higher neutrophil count in peripheral blood, reduced 
killer cell activity and IL-2 production of peripheral lymphocytes after PHA stimulation 
were also reported (Bokor et al., 1992; Klüter et al., 1995). More recently, Bas et al. 
(2001) found that PD patients had a decrease in the number of CD4+ T-helper (TH) cells 
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and B cells, and a rise in activated, CD4+CD25+ T cells in their blood with the number of 
CD8+ cytotoxic T lymphocytes (CTLs) remaining unchanged. 
 
Although some results from schizophrenic patients are contradictory, majority of the 
evidence indicates an immune stimulation like an increase in the number of CD4+ TH cells 
(Henneberg et al., 1990; Muller et al., 1993) and increased plasma level of IL-6 (Maes et 
al., 1995). In some other studies, abnormal functions of T-cell-mediated immunity, as 
evidenced from deficient production of interleukin (IL)-2 and interferon (IFN)-γ and 
elevated level of soluble IL-2 receptor were also reported (Ganguli et al., 1995; Arolt et 
al., 1997). 
 
Higher incidence of cancer in PD patients than age- and sex-matched normal controls 
was also reported (Iwasaki et al., 1990). On the contrary, patients with schizophrenia have 
a reduced incidence of malignancies, despite increased smoking and drinking habits in this 
population (Glubinat et al., 1992). 
 
1.3.2 Pharmacological manipulation of central catecholamines and immunity 
 
Removal of central catecholamines by treatment with neurotoxins, either 6-
hydroxydopamine (6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 
has been widely used to assess immune function in absence of the central catecholamines. 
 
The advantage of 6-OHDA is that it is highly selective for NE nerve fibers, and it does 
not cross the blood-brain barrier (BBB) when administered to adults (Kostrzewa and 
Jacobwitz, 1974). It has been widely used experimentally to deplete DA and NE either 
peripherally or centrally depending on the route of administration. A single intraperitoneal 
(i.p.) injection rapidly (<6h) destroys most NE nerve fibers in 6-OHDA-sensitive tissues; 
NE is depleted by 75-85% in spleen and lymph nodes for at least two weeks (de 
Champlain, 1971; Madden et al., 1994). It is taken up by the high affinity catecholamine 
uptake Ι system, and is blocked by uptake Ι blockers, such as the tricyclic antidepressant 
desipramine (de Champlain, 1971). On uptake, 6-OHDA rapidly destroys the integrity of 
the nerve terminal by a mechanism that is not well understood, resulting in the release of 
NE and other intracellular components from the nerve terminal. In adults, NE cell bodies 
are not destroyed, and reinnervation of the spleen begins as early as five days after 6-
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OHDA treatment (Lorton et al., 1990). A gradual return of NE innervation occurs over the 
next several weeks, with complete recovery of the spleen observed sixty days after 6-
OHDA treatment (Madden, 2001). 
 
On the other hand, systemic administration of MPTP is neurotoxic to central DA 
neurons in several animal species (primates, mice) (Burns et al., 1983; Heikkila et al., 
1984) and can cause Parkinsonism in humans (Langston et al., 1983). The mechanism of 
this action seems to be indirect. MPTP is oxidized in the brain to 1-methyl-4-phenyl-2,3-
dehydropyridinium intermediate (MPDP) and this compound spontaneously oxidation to a 
pyridinium species, 1-methyl-4-phenylpyridine (MPP+). MPTP oxidation is greatly 
decreased by inhibition of monoamine oxidase-B (MAO-B) (e.g., by deprenyl) (Langston 
and Irwin, 1986). In particular, MPTP selectively kills neurons in the zona compacta of 
the substantia nigra. All other areas of the brain appear to be spared, including the locus 
coeruleus and the dopaminergic ventral tegmental area. Thus, MPTP appears to be the 
first neurotoxin to affect a subset of catecholaminergic neurons selectively (Langston and 
Irwin, 1986). 
 
Experimental data in the last two decades have confirmed that central catecholaminergic 
pathways modulate the humoral immune response in the periphery. Initially, Cross et al. 
(1986) reported that mice lesioned centrally with 6-OHDA displayed a profound 
inhibitory effect on the induction of both IgM and IgG primary antibody response to sheep 
red blood cells (SRBC) and immunological memory development, but was without effect 
on the secondary antibody response. More interestingly, these effects were abrogated by 
hypophysectomy three weeks before central 6-OHDA treatment, suggesting that central 
catecholamine depletion modulates immune function via the release of pituitary hormones 
(Cross et al., 1987). In addition, their further study extended these observations by 
showing that central 6-OHDA treatment inhibits the humoral antibody response to T-cell-
dependent antigen trinitrophenyl-keyhole limpet hemocyanin (TNP-KLH), but does not 
affect the response to the T-cell-independent antigen trinitrophenyl-lipopolysaccharide 
(TNP-LPS) in mice (Cross and Roszman, 1988). 
 
Furthermore, ablation of central dopaminergic structures with i.p. injection of MPTP 
reduces the number of IgM plaque-forming cells (PFC) of splenocytes to SRBC in mice 
(Bieganowska et al., 1993). Pre-treatment with i.p. injection of pargyline, a MAO-B 
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inhibitor, which prevents MPTP-induced striatal dopamine depletion, restores this 
humoral immune depression in these animals (Bieganowska et al., 1996). In the study of 
Filipov et al. (2002), selective central dopaminergic depletion in mice by 
intracerebroventricular (i.c.v.) injection of 6-OHDA and pretreatment of desipramine, 
which prevents uptake of 6-OHDA by noradrenergic terminals, resulted in decreases in 
both primary and secondary IgM anti-KLH titers in serum, which could not be restored by 
GBR-12935 dihydrochloride (GBR-12935), a selective DA uptake inhibitor. Primary, but 
not secondary IgG1 anti-KLH titers were also suppressed in these animals, and this 
suppression was not affected by co-administration of GBR-12935 as well. In contrast, the 
IgG2a anti-KLH titers were not influenced by the same treatment (Filipov et al., 2002). 
Similar results were also found in rats. Ten days after bilateral electrolytic destruction of 
brain areas containing DA cell bodies (nuclei A9 and A10) as well as terminal regions of 
the nigrostriatal and mesolimbic dopaminergic systems (nucleus caudatus and nucleus 
accumben), the number of splenocyte rosette-forming cell (RFC) to SRBC is decreased 
(Devoino et al., 1997). They also reported that the administration of SRBC to rats 
produced a marked rise in activity of central dopaminergic system at early stages of the 
immune response formation: the most pronounced elevation in the concentrations of DA 
and its metabolites was observed in the terminal regions of the nigrostriatal and 
mesolimbic dopaminergic systems (nuclei caudatus and accumbens), hypothalamus, 
hippocampus, amygdala within 20 minutes following antigen inoculation; by 60 minutes 
after immunization, DA metabolism had been retained at a high level in all brain regions 
examined; and the concentration of DA returned to control level in the amygdala and in 
the hypothalamus and had a tendency to reach control values in the rest of the structures 
24 hours after antigen administration (Devoino et al., 1997). In addition, Qiu et al. (1996) 
reported that depletion of monoamine neurotransmitters in the brain 24 hours before 
immunization by i.c.v. injection of reserpine, which blocked the assimilation of the 
monoamine neurotransmitters by the vesicula of the nerve terminals and finally exhausted 
these neurotransmitters in the brain, led to a suppression of rat splenocyte anti-SRBC 
response five days after immunization, and during days 2-7 post-immunization in these 
rats, NE contents in the hypothalamus and hippocampus were increased and this paralleled 
to the peak period of antibody response. These results thus indicate a bi-directional 
signaling between the brain monoamines and the immune system as well. 
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However, the modulation of central catecholamine system on peripheral cellular 
immune functions is somewhat unclear. The initial in vitro experiments reported that 
central catecholamine depletion with 6-OHDA in mice resulted in an enhanced splenic 
suppressor T-cell activity, which, in turn, nonspecifically impaired humoral immune 
response only when this subpopulation of T cells was activated cocurrently by antigen 
(Cross et al., 1987). However, central 6-OHDA treatment does not affect the proliferative 
response of splenocytes to both the T-cell mitogen Con A and the B-cell mitogen LPS and 
the proliferative capacity of T cells stimulated with alloantigens in the mixed lymphocyte 
reaction in mice (Cross and Roszman, 1988). Neveu et al. (1992) also reported that four 
weeks after specific dopaminergic depletion in substantia nigra in mice, both Con A- and 
PHA-induced splenocyte proliferation were not changed. However, when tested six weeks 
after the depletion, splenocyte proliferative responsiveness to PHA is enhanced (Neveu et 
al., 1992). In contrast, later results from the same laboratory showed an impairment of 
splenocyte proliferation to both Con A and PHA while LPS-induced proliferation and NK 
cell activity remaining unchanged two weeks after specific dopaminergic depletion in the 
same brain area in mice (Deleplanque et al., 1992, 1994). When the same depletion was 
conducted in nucleus accumbens, no modification of splenocyte proliferative capacity to 
Con A, PHA and LPS, but a decrease in NK cell activity was observed in these animals 
(Deleplanque et al., 1992, 1994). 
 
The association of MPTP-induced striatal DA depletion and immune function was also 
reported by Renoux et al. (1989). In their study, striatal DA level was depressed three 
days after the last of five daily i.p. injection of MPTP, the splenocyte proliferation in the 
presence of Con A was reduced when the PWM-induced proliferation was increased at the 
same time, and T-cell responses to alloantigens in the mixed lymphocyte culture (MLC) 
system were inhibited. These results were further confirmed by Bieganowska et al. (1993) 
who reported decreases in PHA-, Con A- and LPS-induced  splenocyte proliferation seven 
days after i.p. injection of MPTP in mice which can be restored to control values by 
pretreatment with i.p. injection of pargyline. In addition, MPTP i.p. treatment in mice has 
no effects on both phagocytosis of yeast by peritoneal macrophages, and tumor necrosis 
factor (TNF)-α activity of peritoneal macrophages after LPS stimulation (Bieganowska et 
al., 1996). 
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Other experimental evidence also demonstrate that stimulation of D1 dopaminergic 
receptors in different regions of the dopaminergic pathways of the brain is followed by 
either stimulation or inhibition of peripheral NK cell activity (Nistico et al., 1994).  
 
On the other hand, central catecholamines have a consistent role on cellular immune 
functions when tested in vivo. For example, Basu et al. (1995) found MPTP-induced 
striatal dopaminergic depleted mice had an increased growth rate of transplanted 
malignant tumor and a decreased median survival time after the transplantation, tumor 
growth alone was also associated with a decrease in striatal DA level on 10th day after 
tumor transplantation without MPTP injection, and depletion of central DA either 
experimentally by MPTP injection or during tumor growth was accompanied by 
significant immune depression like decreased Con A- or PHA-induced splenocyte 
proliferation, reduced CTL activity, splenic antibody-forming cell population, serum IgM, 
IgG levels and NK cell activity, suggesting central dopaminergic system influences tumor 
growth through the immune network of the host. In rats with a hyperactive dopaminergic 
system, reduced tumor growth, experimental metastasis formation and angiogenesis have 
also been reported (Teunis et al., 2002). A recent experiment by Alaniz and colleagues 
clearly illustrated the differences between in vitro and in vivo experiments: knock-out 
mice lacking dopamine beta-hydroxylase (DBH) (dbh-/- mice) (i.e. they cannot produce 
NE or EPI, but produce dopamine instead) had normal immunological status when housed 
in specific pathogen-free (SPF) conditions, and in the absence of an infecious challenge: 
the total number of leukocytes and the percentages of granulocytes, monocytes, and 
lymphocytes in the blood, and the numbers and subpopulations of cells in the thymus and 
spleen, were similar to age- and sex-matched controls; splenocyte and thymocyte 
proliferation in response to T-cell (Con A and anti-CD3) and B-cell (LPS) mitogens, 
splenocyte production of T-helper-1 (Th1) (IFN-γ) and T-helper-2 (Th2) (IL-4) cytokines, 
and the delayed-type hypersensitivity (DTH) response to TNP-KLH were similar in dbh-/- 
and control mice. All these indicate that dbh-/- mice do not have intrinstic developmental 
or functional immune defects (Alaniz et al., 1999). However, when dbh-/- mice were 
infected with the intracellular pathogens, Listeria monocytogenes (LM) or Mycobacterium 
tuberculosis (MT), or were immunized with a T-cell-dependent antigen, TNP-KLH, they 
were more susceptible to infection, had impaired T-cell function, and had impaired Th1-
cell-dependent-IgG2a antibody production, indicating that physiological catecholamine 
production is not required for normal development of immune system, but plays an 
 - 16 -
important role in the modulation of T-cell-mediated immunity to infection and 
immunization (Alaniz et al., 1999). In addition, Filipov et al. (2002) reported that 
selective unilateral DA depletion by intratriatal injection of 6-OHDA in mice impaired 
subsequent in vivo immune responses to LM as well as to KLH, partial sparing of striatal 
DA levels by a co-administration of GBR-12935 eliminated the detrimental effect of 6-
OHDA treatment on host resistance to LM, but not the impairment of antibody and DTH 
response to KLH. Mice administered with the combination of 6-OHDA and GBR12935 
have approximately 35% more DA than the 6-OHDA along group, but about 60% less DA 
in the lesioned striatum than control animals, suggesting that  antibody and DTH 
responses are more sensitive to the striatal DA depletion (Filipov et al., 2002). 
 
The results concerning the association between central catecholamine depletion and 
peripheral lymphocyte distribution remain controversial. When MPTP-induced striatal DA 
depletion decreases T-cell percentage and increases B-cell percentage in the spleen 
(Renoux et al., 1989), MPTP i.p. treatment can not affect the T-cell subpopulations in the 
spleen but reduces the percentage of L3T4 T cells in peripheral blood in mice 
(Bieganowska et al., 1996). When 6-OHDA injected into substantia nigra bilaterally in 
rats fails to affect the percentage of activated CD4+CD25+ T cells in mesenteric lymph 
nodes, bilateral injection of MPP+ into striatum causes an increase in it (Bas et al., 2001). 
 
By the way, both Neveu et al. (1992) and Deleplanque et al. (1992, 1994) reported that 
central dopaminergic pathway was asymmetrically involved in modulation of immune 
response. They oberserved that after 6-OHDA-induced dopaminergic lesion of the 
substantia nigra in mice, the proliferative capacity of splenocyte was depressed only in 
right-lesioned group. Similarly, after lesioning of the nucleus accumbens, NK cell activity 
was depressed only in left-lesioned mice. Filipov et al. (2002) also found left-side DA 
depletion reduced the in vivo immune responses both to LM and to KLH in mice. 
 
The time at which  immune assays are performed after central catecholamine depletion 
also appears to be crucial to the results observed. Although no effects were reported on 
cellular immune variables two days after 6-OHDA injection into the cisterna magna 
(Cross and Roszman, 1988), mitogen-induced T-cell proliferation was proved to be 
suppressed two weeks after lesioning central dopaminergic structures in mice 
(Deleplanque et al., 1992). However, when immunological variables were analysed six 
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weeks after central dopaminergic lesioning, a significant enhancement in lymphocyte 
proliferation was observed (Neveu et al., 1992). 
 
1.4 Aim of the study 
 
It is well known that the central nervous system affects the immune response via various 
pathways. This is primarily achieved by several neurotransmitters, neuropeptides, 
hormones and cytokines. Among these neural mediators, central catecholamines play an 
important role, which has been proved by numerous clinical and experimental 
investigations. Patients with PD or schizophrenia, both of which are neurological 
disorders involving central catecholamine disfunction, are found to have significant 
abnormalitis in humoral and cellular immune responses. Numerous scientific 
investigations have also demonstrated that central catecholaminergic pathways play a 
pivotal role in modulating peripheral humoral and cellular immune functions both in vitro 
and in vivo. However, the modulation of central catecholamine depletion on peripheral 
cellular immune response remains somewhat unclear. To address this uncertainty, we 
designed a set of experiments to analyse the influence of central catecholamine depletion 
with the neurotoxin 6-OHDA on peripheral cellular immune functions. 
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2. Material and Methods 
 
2.1 Animals 
 
Naïve male Dark Agouti rats (Harlan Laboratories, Borchen, Germany), weighing 
between 220 and 250 g were used. All rats were allowed to habituate to the animal 
laboratory conditions for three weeks before starting the experiments. Animals were 
individually housed in standard plastic laboratory cages (40cm × 26cm × 15cm high) with 
a wire mesh lid. Cages were kept in an air-conditioned, sound-proof holding room at an 
ambient temperature of 24.0±0.5°C. The animals had access to standard lab chow and tap 
water ad libitum. A 12 hour light/dark cycle was maintained throught the experiment with 
lights off at 0700. All animal procedures were carried out as approved by the ethic 
committee of the Medical Faculty, University of Duisburg-Essen, Germany. 
 
2.2 Experimental design 
 
To centrally deplete catecholamines, experimental animals received bilateral injections 
of 6-OHDA into lateral ventricles. Control animals were injected only with the vehicle. 
Two, four, and seven days later, experimental and control animals were sacrificed by 
decapitation. Immediately afterwards, spleen and blood samples were obtained to measure 
the proliferative capacity of lymphocytes and cytokine production. Brain and spleen 
samples were collected and stored (-80°C) for later catecholamine determination. 
 
2.3 Central catecholamine depletion 
 
Central catecholamines were depleted by stereotaxically injecting 100 µg of freshly 
prepared 6-OHDA (Sigma, Taufkirchen, Germany) dissolved in a volume of 10 µl of 
ascorbate solution (2 mg/ml of ascorbic acid in sterile saline solution) as a vehicle into the 
lateral ventricles of the animals (5µl/ventricle). The stereotaxic coordinates used were ± 
1.4 mm lateral, - 3.4 mm ventral, and -0.8 mm anterior with respect to bregma, according 
to a stereotaxic atlas (Paxinos and Watson, 1986).  
 
2.4 Catecholamine determination 
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Levels of norepinephrine, dopamine, epinephrine and serotonin in the spleen and brain 
tissues (hypothalamus and cortex) were measured by high-performance liquid 
chromatography (HPLC) as described previously (van der Hoorn et al., 1989). Briefly, 
each sample was homogenized in 0.1-M perchloric acid containing 0.1-mM EDTA. 
Following centrifugation, 25 µl of the supernatant was used for catecholamine extraction 
by established methods (Smedes et al., 1982). Catecholamine concentrations were anlyzed 
by HPLC (Gynkotek, Germany) and expresessed as ng/mg wet tissue. Intra-assay 
variability was < 10%. 
 
2.5 Splenocytes preparation 
 
After sacrificing the rats, spleens were removed aseptically, then splenocytes were 
released from tissue by injecting cell culture medium (RPMI 1640 (PAA, Linz, Austria) + 
7% fetal calf serum (FCS) (Sigma) inactivated + 1% penicillin (Sigma)) into spleens with 
a syringe. After washed with phosphate buffered saline (PBS) (ICN, USA), the 
erythocytes were removed by shaking with haemolysis buffer containing NH4Cl and Tris 
(ICN, USA) for 10 minutes. Then the cells were washed with PBS twice again, 
resuspended with 5 ml of cell culture medium and counted under a microscope (Olympus, 
Japan). 
 
2.6 Con A-induced splenocyte proliferation 
 
Splenocytes were adjusted to 1.6 ×106 cells/ml in cell culture medium (RPMI 1640 + 
7% FCS inactivated + 1% penicillin) and 100µl of cell suspension were added in triplicate 
to 96-well flat-bottom cell culture plates (NUNC, Denmark) cultured for 72 h in the 
presence of Con A (final concentrations: 0, 1.25 and 2.5 µg/ml) at 37°C in a 5% CO2 
incubator (Heraeus, Germany). Pre-test showed the optimal concentration of Con A was 
2.5 µg/ml. After 48 h of mitogen stimulation the cells were pulsed with 20 µl/well 
[3H]thymidine (0.5 µCi) and harvested 24 h later. Radioactivity was measured using a β-
counter (WALLAC Oy, Finland). 
 
2.7 Peripheral lymphocyte preparation 
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After decapitation, blood was put into tubes containing EDTA. Peripheral mononuclear 
cells were isolated and collected according to a standard Ficoll protocol. After washed 
with PBS (ICN, USA),  the mononuclear cells were resuspended with 5 ml of cell culture 
medium (RPMI 1640 + 7% FCS inactivated + 1% penicillin) and transferred to a sterile 
petri-dish with 10 ml of cell culture medium inside for seperating monocytes from 
lymphocytes. After incubated at 37°C in a 5% CO2 incubator (Heraeus, Germany) for 30 
minutes, supernatants which containing lymphocytes were collected and washed with PBS 
(ICN, USA) again. Then the cells were resuspended with 1 ml of cell culture medium, 
counted under a microscope (Olympus, Japan). 
 
2.8 Con A-induced peripheral lymphocyte proliferation 
 
Peripheral lymphocytes were adjusted to 1.6 ×106 cells/ml in cell culture medium 
(RPMI 1640 + 7% FCS inactivated + 1% penicillin) and 100µl of cell suspension were 
added in triplicate to 96-well flat-bottom cell culture plates (NUNC, Denmark) cultured 
for 72 h in the presence of Con A (final concentrations: 0, 1.25 and 2.5 µg/ml) at 37°C in 
a 5% CO2 incubator (Heraeus, Germany). Pre-test showed the optimal concentration of 
Con A was 2.5 µg/ml. After 48 h of mitogen stimulation the cells were pulsed with 20 
µl/well [3H]thymidine (0.5 µCi) and harvested 24 hours later. Radioactivity was measured 
using a β-counter (WALLAC Oy, Finland). 
 
2.9 ELISA detection for IL-2 and IFN-γ in splenocyte proliferation supernatant 
 
2.9.1 ELISA detection for IL-2 in splenocyte proliferation supernatant 
 
Splenocytes were adjusted to 1.6×106 cells/ml in cell culture medium (RPMI 1640 + 7% 
FCS inactivated + 1% penicillin), then cultured for 48 h in the presence of Con A (1.25 
µg/ml) at 37°C in a 5% CO2 incubator. Subsequently, plates were centrifuged and 50 µl of 
supernatant was removed for IL-2. IL-2 was assayed using commercial enzyme-linked 
immunosorbent assay (ELISA) kits for the detection of rat IL-2 (Biosource International, 
CA, USA).  
 
Briefly, 12.5 µg of coating antibody were diluted in 10ml coating buffer A to a final 
concentration 1.25 µg/ml. Then 100 µl of diluted coating antibody was placed in 96 wells 
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U-bottomed flexible microtiter plates (Biosource International, CA, USA). The plates 
were covered and incubated overnight at 4°C. Afterward the coating antibody was 
aspirated from the wells and tapped on absorbent paper to remove excess liquid, 300 µl of 
blocking solution were then added to each well, covered and incubated at room 
temperature for two hours. Once again the blocking solution was aspirated from the wells 
and tapped on absorbent paper, and then the microplates were washed three times with 
wash solution. 
 
Twenty-one ng of IL-2 standard were diluted in 2.1 ml standard diluent. Samples were 
diluted to 1:30, and then 100 µl of either standard or samples were added to the 
appropriate wells in duplicate. Plates were then incubated at room temperature for 90 
minutes, after which the solution was aspirated from the wells and the plates were washed. 
Then 0.5 µg of detection antibody was added to each well, incubating the mixture at room 
temperature for 60 minutes. 
 
Three µg of Streptavidin HRP conjugate were diluted in 10 ml standard diluent, and 100 
µl were added to each well, incubating at room temperature for 45 minutes. Finally 100 µl 
of tetramethyl benzidine (TMB) were added to each well and incubated in the dark at 
room temperature for 30 minutes. The reaction was stopped by addition of 100 µl of stop 
solution. 
 
Microplates were read at 450 nm (Mikrotek, Germany) within 30 minutes of adding the 
stop solution, and the average optical density was calculated at 450 nm for all standards, 
controls and samples. The concentration of each unknown sample was detected from the 
standard curve. The backgroud was subtracted from all groups. 
 
2.9.2 ELISA detection for IFN-γ in splenocyte proliferation supernatant 
 
Splenocytes were adjusted to 1.6×106 cells/ml in cell culture medium (RPMI 1640 + 7% 
FCS inactivated + 1% penicillin), then cultured for 48 h in the presence of Con A (1.25 
µg/ml) at 37°C in a 5% CO2 incubator. Subsequently, plates were centrifuged and 50 µl of 
supernatant was removed for IFN-γ. IFN-γ was assayed using commercial ELISA kits for 
the detection of rat IFN-γ (U-CyTech, Utrecht, The Netherlands). 
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Briefly, the coating antibody was diluted to 1:200 in PBS. Then 100 µl of diluted 
coating antibody was placed in 96 wells U-bottomed flexible microtiter plates (U-CyTech, 
Utrecht, The Netherlands). The plates were covered and incubated overnight at 4°C. 
Afterward the coating antibody was aspirated from the wells and tapped on absorbent 
paper to remove excess liquid, 300 µl of blocking solution were then added to each well, 
covered and incubated at 37ºC for one hour. Once again the blocking solution was 
aspirated from the wells and tapped on absorbent paper, and then the microplates were 
washed six times with wash solution. 
 
Seven point five ng of IFN-γ standard were diluted in 500 µl distilled water. Samples 
were diluted to 1:30, and then 100 µl of either standard or samples were added to the 
appropriate wells in duplicate. Plates were then incubated at 37ºC for two hours, after 
which the solution was aspirated from the wells and the plates were washed. The detection 
antibody was diluted to 1:100 in PBS containing 0.5% bovine serum albumin (BSA) and 
0.05% Tween-20. Then 100 µl of diluted detection antibody was added to each well, 
incubating the mixture at 37ºC for one hour. 
 
The Streptavidin-HRP polymer was diluted to 1:100 in PBS containing 0.5% BSA and 
0.05% Tween-20, and 100 µl were added to each well, incubating at 37ºC for one hour. 
Finally 100 µl of TMB were added to each well and incubated in the dark at room 
temperature for 15 minutes. The reaction was stopped by addition of 50 µl of stop 
solution. 
 
Microplates were read at 450 nm (Mikrotek, Germany) within 30 minutes of adding the 
stop solution, and the average optical density was calculated at 450 nm for all standards, 
controls and samples. The concentration of each unknown sample was detected from the 
standard curve. The backgroud was subtracted from all groups. 
 
2.10 RT-PCR analysis of IL-2 mRNA expression 
 
Splenocytes were adjusted to 5 × 106 cells/ml in culture medium (RPMI 1640 + 7% FCS 
inactivated + 1% penicillin),  one ml of the cell suspension were added in six-well tissue 
culture plates (Falcon) in the presence of Con A (1.25 µg/ml) and incubated for six hours, 
then harvested for reverse transcriptase-polymerase chain reaction (RT-PCR). 
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 2.10.1 Total RNA isolation 
 
Reagents: The denaturing solution was 4-M Guanidinium thiocyanate (GTC) (Sigma, 
USA), 25mM sodium citrate (Sigma, USA), pH 7, 0.5% sarcosyl (Sigma, USA), 0.1 M 2-
mercaptoethanol (Sigma, USA). The stock solution was made as follows: 236.25 g 
guanidinium thiocyanate was dissolved with 500 ml DEPC, 4.18 ml 3-M NAOAc (Sigma, 
USA) and 3.75 ml β-mercaptoethanol (Sigma, USA). 
 
5 × 106 splenocytes were denatured with 700 µl of 4-M GTC (Sigma, USA) after 
cultured for six hours in the presence of Con A (1.25 µg/ml). Sequentially, 50 µl of 2-M 
sodium acetate, 560 µl of Phenol (Sigma, USA), and 280 µl of phenol-chloroform-
isoamyl alcohol mixture (Sigma, USA) were added to the cells, with thorough mixing by 
inversion after the addition of each reagent. The final suspension was cooled on ice for 20 
minutes. Samples were centrifuged at 13,000 g for 20 minutes at 4°C. After 
centrifugation, RNA was present in the aqueous phase where DNA and proteins were 
present in the interphase and phenol phase. The aqueous phase was transferred to a fresh 
tube (Eppendorf, Germany), mixed with 500 µl of isopropanol (JT Baker, Netherland), 
and then placed at −20°C for at least two hours to precipitate RNA. Sedimentation at 
13,000 g for 20 minutes was again performed and the resulting RNA pellet was dried for 
one hour, and then was dissolved in 300 µl 4-M GTC, and precipitated with 300 µl 
isopropanol at −20°C for at least two hours. After centrifugation at 13,000 g at 4°C for 20 
minutes, the RNA pellet was resuspended in 75% ethanol, sedimented, air dried for 30 
minutes, and dissolved in 10 µl DEPC at 59°C for 10 minutes. One µl of the RNA 
solution was removed and diluted with 99 µl DEPC. The RNA concentration was 
measured by SmartSpec 3000 (BIO-RAD, USA). 
 
2.10.2 Reverse transcription 
 
RNA was amplified by RT with an Oligo (dT-15) primer (Gibco/BRL, USA). One µg of 
total RNA sample and 2.5 µl of oligo-dT 15 were added to a sterile Rnase-free 
microcentrifuge tube (Eppendorf, Germany), filling the total volume with DEPC up to 12 
µl. The tubes were heated to 68°C for 15 minutes to melt secondary structure within the 
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template, and then cooled immediately on ice to prevent secondary structure from 
reforming. Tubes were then spun briefly to collect the solution at the bottom of the tubes. 
The following components were then added to the tubes: 5 µl of M-MLV 5 × Reaction 
buffer (Promega, USA); 1.25 µl of 10 mM dATP, 1.25 µl of 10 mM dCTP, 1.25 µl of 10 
mM dGTP, 1.25 µl of 10 mM dTTP (Promega, USA); 200 units of M-MLV Reverse 
transcriptase (Promega, USA). Finally, the nuclease-free water was added to make the 
final volume of 25 µl. The solution was mixed gently by flicking the tube and incubated 
for 90 minutes at 45°C, and then for 30 minutes at 52°C. The reation was halted by 
heating to 96°C for 15 minutes and this was followed by cooling on ice. 
 
2.10.3 Amplification of specific complementary DNA (cDNA) 
 
Specific cDNA products corresponding to mRNA for IL-2 and GAPDH were amplified 
using PCR.  The following components were added to a microcentrifuge tube sitting on 
ice: five µl of 10 × PCR buffer (Gibco/BRL, USA), final concentration was 1 ×; four µl of 
10 mM dNTP mixture (Promega, USA), final concentration was 0.2 mM each; 1.5 µl of 
50 mM MgCl2 (Gibco/BRL, USA), final concentration was 1.5 mM, one µl of 5’ primer, 
one µl of 3’ primer (MWG-Biotech, Germany), final concentration was 0.5 µM each; one 
µl of cDNA from RT reaction; 0.2 µl of Taq DNA polymerase (5 U/µl) (Gibco/BRL, 
USA). Autoclaved distilled water was added to bring the final volume to 50 µl. The 
concents of tube were mixed, and centrifuged briefly to collect the contents to the bottom. 
 
Tubes were incubated in a Mastercycler 5330 system at 95°C for three minutes to 
completely denature the template. The program was set up as follows: (1). Denatured for 
30 seconds at 94°C; (2). Annealed primers for 30 seconds at 61°C for GAPDH, 54°C for 
IL-2; (3). Extended the primers for 30 seconds at 72°C. The PCR technique employed 25 
cycles of amplification for GAPDH and 30 cycles for IL-2. Incubation for an additional 10 
minutes was carried out at 72°C and the reaction was maintained at 4°C. The amplified 
PCR products were identified by electrophoresis of 20 µl sample aliquots on 1.5% agarose 
gel (Gibco/BRL, USA), stained with 0.5 µg/ml of ethidium bromide (Roth, Germany). 
The products were visualised by UV transillumination and the gel was photographed. 
Specific products were identified by size in relation to a known 100 bp oligonucleotide 
DNA ladder (Gibco/BRL, USA) run with each gel. Imaging of the PCR products was 
performed using the fluorescence imaging analyzer (ITF, Germany). The image of 
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ethidium bromide stained DNA fragments were quantified using Aida 2 beta software. 
Relative fluorescent units (ruf) were used as an index of mRNA level. GAPDH served as 
an internal control. The data were expressed as amount of IL-2 produce over the amout of 
GAPDH produce (IL-2/GAPDH). Amplifying cDNA with PCR for GAPDH and IL-2, the 
following primers were used for gene amplification: 
GAPDH (sense) 
5’ –ACC ACA GTC CAT GCC ATC AC-3’ 
GAPDH (antisense) 
5’ –TCC ACC ACC CTG TTG CTG TA-3’ 
IL-2 (sense) 
5’ –ATG TAC AGC ATG CAG CTC GCA TC-3’ 
IL-2 (antisense) 
5’ –TTA CTG AGT CAT TGT TGA GAT GAT GCT TTG-3’ 
 
2.11 Statistical analysis 
 
One way analysis of variance (ANOVA) and Fisher post hoc test were used to examine 
statistical differences between the groups. Data are expressed as means ± SEM. p < 0.05 
was considered statistically significant. 
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3. Results 
 
3.1 Effects of i.c.v. 6-OHDA treatment on central and peripheral catecholamine 
concentrations 
 
Six-OHDA, a neurotoxin which is highly selective for catecholamine nerve fibers, has 
been widely reported to deplete central catecholamines when administered centrally. In 
order to identify the severe, selective and systematic destruction of central 
catecholaminergic neurons by i.c.v. 6-OHDA treatment, two, four, and seven days after 
i.c.v. injection with 6-OHDA or vehicle, hypothalamus, cortex and spleen tissue samples 
were collected for catecholamine analysis by HPLC. These analyses demonstrated a 
pronounced reduction of NE (p< 0.01 on the second, fourth and seventh day after the 
treatment, respectively; Fig. 1a), EPI (p< 0.05 on the fourth and seventh day after the 
treatment, respectively; Fig. 1b) and DA (p< 0.05 on the seventh day after the treatment; 
Fig. 1c) levels in the hypothalamus of animals treated with i.c.v. 6-OHDA compared with 
controls. Similar results were found in the cortex, while the EPI concentrations were under 
the detectable limit, NE (p< 0.01 on the seventh day after the treatment; Fig. 2a) and DA 
(p< 0.01 on the second, fourth and seventh day after the treatment, respectively; Fig. 2b) 
levels significantly decreased in 6-OHDA injected animals, compared to the controls. One 
of the advantages of 6-OHDA is that it does not cross the BBB when administered to 
adults, so it has been used experimentally to deplete catecholamines either peripherally or 
centrally depending upon the route of administration. However, in the present study, we 
observed a significant but transient reduction in splenic concentrations of NE (p< 0.05; 
Fig. 3a) and EPI (p< 0.05; Fig. 3b) in 6-OHDA treated animals, compared to the controls 
on the fourth day after the injection. Although the DA level in the spleen of animals 
treated with i.c.v. 6-OHDA also decreased a lot compared with controls on the fourth day 
after the treatment, the statistical analysis revealed this decrease was not significant (Fig. 
3c). Furthermore, in order to assess 6-OHDA’s specificity for catecholamine depletion, 
serotonin levels were also assessed in hypothalamus, cortex and spleen by HPLC on the 
seventh day after the injection. These analyses revealed that there was no effect on 
serotonin levels in all these tissues by i.c.v. 6-OHDA treatment (Fig. 4). 
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Figure 1. The effects of i.c.v. 6-OHDA treatment on 
catecholamine levels in hypothalamus. Dark Agouti rats received 
i.c.v. 6-OHDA (n=8, ●) or vehicle (n=8, □) injection and were 
killed 2, 4 and 7 days after injection and brain tissues were 
collected for measurement of norepinephrine, epinephrine and 
dopamine concentrations by HPLC. Results are expressed as mean 
± SEM. *p<0.05, **p<0.01 compared to vehicle injection. 
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Figure 2. The effects of i.c.v. 6-OHDA treatment on 
catecholamine levels in cortex. Dark Agouti rats received i.c.v. 6-
OHDA (n=8, ●) or vehicle (n=8, □) injection and were killed 2, 4 
and 7 days after injection and brain tissues were collected for 
measurement of norepinephrine, epinephrine and dopamine 
concentrations by HPLC (epinephrine concentration was under the 
detectable limit). Results are expressed as mean ± SEM. **p<0.01 
compared to vehicle injection. 
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Figure 3. The effects of i.c.v. 6-OHDA treatment on 
catecholamine levels in spleen. Dark Agouti rats received i.c.v. 6-
OHDA (n=8, ●) or vehicle (n=8, □) injection and were killed 2, 4 
and 7 days after injection and spleen tissues were collected for 
measurement of norepinephrine, epinephrine and dopamine 
concentrations by HPLC. Results are expressed as mean ± SEM. 
*p<0.05 compared to vehicle injection. 
 - 30 -
 
 
Figure 4. The effects of i.c.v. 6-OHDA treatment on serotonin 
levels in hypothalamus, cortex, and spleen. Dark Agouti rats 
received i.c.v. 6-OHDA (n=8, ■) or vehicle (n=8, □) injection and 
were killed 7 days after injection. Brain and spleen tissues were 
collected for measurement of serotonin concentration by HPLC. 
Results are expressed as mean ± SEM. 
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3.2 Effects of central catecholamine depletion on lymphocyte proliferation 
 
In order to identify the influence of central catecholamine depletion by i.c.v. 6-OHDA 
injection on peripheral cellular immune response, four and seven days after the 6-OHDA 
treatment, the proliferative capacity of lymphocytes in the spleen and in peripheral blood 
was analysed. As shown in Figure 5, the proliferative response of splenocytes in the 
presence of Con A (final concentrations: 1.25 and 2.5 µg/ml), a T-cell mitogen, was not 
affected four days after the injection compared to the control group. However, a 
pronounced decrease in splenocyte proliferation in the presence of Con A (final 
concentrations: 1.25 and 2.5 µg/ml) seven days after the treatment compared with the 
controls was observed (p< 0.05 at both concentrations of Con A, respectively; Fig. 6). In 
the next step, we investigated whether this effect was limited to the spleen. Therefore, the 
proliferative capacity of peripheral blood lymphocytes at the same time point was tested. 
In parallel to the reduced splenocyte responsiveness, seven days after the treatment, we 
observed a significant reduction in the proliferative response of peripheral blood 
lymphocytes in the presence of Con A (final concentrations: 1.25 and 2.5 µg/ml) in 
animals with i.c.v. 6-OHDA injection as compared to the controls (p< 0.05 at both 
concentrations of Con A, respectively; Fig. 7). 
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Figure 5. Con A (final concentrations: 0, 1.25 and 2.5µg/ml)-induced 
proliferation of splenocytes 4 days after i.c.v. treatment with 6-OHDA (n=8, 
●) or vehicle (n=8, □). Results are expressed as mean ± SEM. 
 
 
 
Figure 6. Con A (final concentrations: 0, 1.25 and 2.5µg/ml)-induced 
proliferation of splenocytes 7 days after i.c.v. treatment with 6-OHDA (n=8, 
●) or vehicle (n=8, □). Results are expressed as mean ± SEM. *p<0.05 
compared to vehicle injection. 
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Figure 7. Con A (final concentrations: 0, 1.25 and 2.5µg/ml)-induced 
proliferation of peripheral blood lymphocytes 7 days after i.c.v. treatment 
with 6-OHDA (n=8, ●) or vehicle (n=8, □). Results are expressed as mean ± 
SEM. *p<0.05 compared to vehicle injection. 
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3.3 Effects of central catecholamine depletion on splenocyte cytokine production 
 
Since IL-2, which secreted by Th1 cells, have been proved to be of crucial importance 
for lymphocyte proliferation, we measured IL-2 concentration in the supernatant of Con A 
(final concentration 1.25 µg/ml) stimulated splenocytes seven days after central 
catecholamine depletion by i.c.v. 6-OHDA treatment to elucidate the possible cellular 
mechanisms of the reduced lymphocyte proliferation. As shown in Figure 8, experimental 
6-OHDA treated animals had a significantly reduced splenic IL-2 production compared to 
the vehicle control group (p< 0.05). 
 
IFN-γ, secreted by Th1 cells as well, have also been reported to play a role in 
determining the differentiation pathway of precursor TH cells into effecotr Th1/Th2 cells 
and the antibody isotype produced by B cells. In order to further confirm the suppression 
of cytokine production from lymphocytes, especially from Th1 cells by central 
catecholamine depletion, IFN-γ was also analysed from the supernatants of the Con A 
(final concentration 1.25 µg/ml) stimulated splenocytes at the same time point. The 
experimental animals also showed a significant reduction in IFN-γ production compared 
to the controls (p< 0.05; Fig. 9). 
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Figure 8. The effects of i.c.v. 6-OHDA treatment on 
splenocyte IL-2 production after Con A stimulation. 7 days 
after the i.c.v. injection of 6-OHDA (n=8, ■) or vehicle (n=8, 
□), animals were killed and splenocytes were collected and 
incubated for 48h in the presence of Con A (final 
concentration 1.25 µg/ml), and the supernatant was removed 
for IL-2 analysis using ELISA kits. Results are expressed as 
mean ± SEM. *p<0.05 compared to vehicle injection. 
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Figure 9. The effects of i.c.v. 6-OHDA treatment on 
splenocyte IFN-γ production after Con A stimulation. 7 days 
after the i.c.v. injection of 6-OHDA (n=8, ■) or vehicle (n=8, 
□), animals were killed and splenocytes were collected and 
incubated for 48h in the presence of Con A (final 
concentration 1.25 µg/ml), and the supernatant was removed 
for IFN-γ analysis using ELISA kits. Results are expressed as 
mean ± SEM. *p<0.05 compared to vehicle injection. 
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3.4 Effects of central catecholamine depletion on splenocyte IL-2 mRNA expression 
 
Having demonstrated that central catecholamine depletion by i.c.v. 6-OHDA treatment 
can decrease the proliferative capacity of lymphocytes as well as the splenocyte 
production of both IL-2 and IFN-γ in the presence of Con A, We were interested in 
determining at what level the reduction of splenocyte IL-2 production by the central 6-
OHDA treatment occurred. In order to answer this question, the IL-2 mRNA expression in 
Con A (final concentration 1.25 µg/ml) stimulated splenocytes were analysed seven days 
after the treatment. Consistent with the observed effects of i.c.v. 6-OHDA injection on 
lymphocyte proliferation and splenocyte cytokine (IL-2 and IFN-γ) production, 
experimental 6-OHDA treated animals showed a pronounced suppression of IL-2 mRNA 
expression in the Con A (final concentration 1.25 µg/ml) stimulated splenocytes as 
compared to the vehicle injected controls (p<0.05; Fig. 10a). 
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Figure 10. The effects of i.c.v. 6-OHDA treatment on splenocyte IL-2 mRNA 
expression (a and b) after Con A stimulation. 7 days after the i.c.v. injection of 
6-OHDA (n=8, ■) or vehicle (n=8, □), animals were killed and splenocytes were 
collected and incubated for 6h in the presence of Con A (final concentration 
1.25 µg/ml), and then the cells were collected for IL-2 mRNA expression 
detection using RT-PCR. Results are expressed as mean ± SEM. *p<0.05 
compared to vehicle injection. 
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4. Discussion 
 
The present investigation demonstrates that a selective and systematic depletion of 
central catecholamines by i.c.v. 6-OHDA injection influences peripheral cellular immune 
functions by decreasing lymphocyte proliferation in spleen and peripheral blood as well as 
splenocyte cytokine production at both protein (IL-2 and IFN-γ) and mRNA (IL-2) levels, 
thereby further contributing to our understanding of the role that central catecholamines 
play in regulating peripheral cellular immune response. 
 
Intracerebroventricular injection of neurotoxin 6-OHDA causes severe, selective and 
systematic destruction of central catecholaminergic neurons. Currently, 6-OHDA, together 
with MPTP, are the two most widely used models of PD (Tolwani et al., 1999). A single 
central administration of 6-OHDA depletes the hypothalamus, midbrain and pons-medulla 
of NE and the striatum of DA in mice (Cross et al., 1986). In the present study, we also 
observed a severe, selective and systematic central catecholamine depletion in rats 
following i.c.v. 6-OHDA treatment. Two, four and seven days after the injection, NE, DA 
and EPI levels in the hypothalamus and in the cortex were significantly reduced in 
experimental animals than in the controls. Moreover, no effects of i.c.v. 6-OHDA 
injection on serotonin contents in the same tissues were found on the seventh day after the 
treatment, confirming the highly specificity of 6-OHDA for catecholaminergic nerve 
fibers. 
 
Furthermore, although no effects of central catecholamine depletion with 6-OHDA on 
splenocyte and peripheral lymphocyte proliferation were found four days after the 
injection, the proliferative capacity of lymphocytes in spleen and peripheral blood to Con 
A, a T-cell mitogen, was significantly inhibited in experimental rats than in the controls 
seven days after the treatment. Since IL-2 have been shown to be of crucial importance for 
lymphocyte proliferation (Chouaib et al., 1985), we also measured the IL-2 production 
and mRNA expression of splenocytes in the presence of Con A seven days after i.c.v. 6-
OHDA injection. Our data shows that splenic IL-2 production as well as mRNA 
expression is also significantly reduced by central catecholamine depletion. These 
observations are not only similar to those reported by Renoux et al. (1989) and 
Bieganowska et al. (1993) who found that splenocyte proliferation in the presence of Con 
A was inhibited by central catecholamine depletion, but also in agreement with those 
reported by Klüter et al. (1995) who found that IL-2 production of peripheral lymphocytes 
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after PHA stimulation was reduced in patients with PD. Moreover, our findings that 
central catecholamine depletion suppresses splenic IL-2 production not only at protein 
level, but also at mRNA level, and central catecholamine depletion suppresses splenocyte 
proliferation is associated with a marked synergistic decrease in IL-2 production, which 
indicating the inhibition of IL-2 production contributes to the suppressed splenocyte 
proliferation after the depletion, extend these previous observations. 
 
Two CD4+ TH cell subsets have been identified and are characterized by the cytokines 
they secrete, Th1 cells secrete IFN-γ and IL-2, while Th2 cells secrete IL-4, IL-5, IL-6 and 
IL-10 (Mosmann et al., 1991). Th1 cells direct cellular immune response through the 
production of IL-2 to promote proliferation and expansion of CD4+ T cells, and IFN-γ to 
play a role in determining the differentiation pathway of precursor TH cells into effector 
Th1/Th2 cells and the antibody isotype produced by B cells. In vitro and in vivo, IFN-γ-
producing Th1 cells induce B cells to produce IgG2a (Stevens et al., 1988; Finkelman et 
al., 1990). In the present study, we also found a significant reduction of splenocyte IFN-γ 
production in the presence of Con A seven days after i.c.v. 6-OHDA injection, which, 
together with the decreased splenocyte IL-2 production and mRNA expression, indicate 
Th1-cell activity is inhibited by central catecholamine depletion. Our results agree with 
those reported by Alaniz et al. (1999) who showed that splenocytes from dbh-/- mice 
produced less Th1 cytokines (IFN-γ and TNF-α) and more Th2 cytokine (IL-10) than 
splenocytes from controls in response to stimulation with MT culture filtrate proteins 
(CFP) and anti-CD3 four weeks after the infection by MT, and that after immunized with 
TNP-KLH, compared with dbh+/- controls, dbh-/- mice had lower titers of IFN-γ-dependent 
IgG2a anti-TNP antibody, but similar amouts of IgG1 and IgM anti-TNP antibody, which 
suggesting Th1 responses are impaired in dbh-/- mice in response both to immunization 
and to infection. Cross and Roszman (1988) also reported that central 6-OHDA treatment 
in mice inhibited the humoral antibody response to T-cell-dependent antigen TNP-KLH, 
but did not affect the response to the T-cell-independent antigen TNP-LPS. Taken 
together, it is likely that central catecholamine depletion inhibits peripheral cellular as 
well as humoral immune responses by reducing the activity of Th1 cells. 
 
More interestingly, with no changes in splenic catecholamine concentrations were found 
two days after i.c.v. 6-OHDA injection, a transient but significant reduction in NE and 
EPI concentrations in the spleen was observed four days after the treatment in 
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experimental animals compared with the controls. Previous investigations have 
demonstrated that the spleen is innervated by NE-containing sympathetic nerve fibers 
(Felten et al., 1987a; Felten and Olschowka, 1987). However, 6-OHDA depletes NE by 
75-85% in spleen and lymph nodes for at least two weeks when administered peripherally 
(Madden et al., 1994), and it does not cross the BBB when administered to adults 
(Kostrzewa & Jacobwitz, 1974). Therefore, this transient decrease of splenic NE and EPI 
concentrations is not due to the direct toxicity of 6-OHDA on sympathetic nerve fibers in 
the spleen, but a result of the modulation of central catecholamine depletion on peripheral 
sympathetic output. 
 
At present, the precise mechanism of how central catecholamine depletion alters 
peripheral immunity is still unclear. However, the present data suggest that peripheral 
SNS plays a role in these effects. 
 
The central catecholaminergic system seems to be involved in sensing and modulating 
peripheral immune functions. Significant alterations of catecholamine activity occur in 
specific brain regions during an immune response (Besedovsky et al., 1983; Qiu et al., 
1996; Devoino et al., 1997), indicating that this central neurotransmission system is 
involved in the afferent arm of immune-to-brain communication. On the other hand, 
central noradrenergic networks can exert direct efferent immunomodulatory actions 
through fibres innervating immune organs (Bellinger et al., 1989; Felten, 1993). 
Specifically, it has been shown that the splenic sympathetic innervation is under the 
control of the ventromedial hypothalamic nucleus (Okamoto et al., 1996). Furthermore, 
these splenic efferent fibres originate from the sympathetic thoracolumbar column which 
is under the control of the A5 and A7 noradrenergic brainstem nuclei (Cano et al., 2001). 
As the neuronal activity (firing rates and patterns) of brain nuclei receiving projections 
from catecholaminergic structures changes after central catecholamine depletion (Ni et al., 
2000, 2001), we hypothesize that centrally administrated 6-OHDA affects peripheral 
catecholamine output, with its immunomodulatory effects, by causing discrete alterations 
in central neural firing. 
 
Evidence in the last decade has shown that NE-containing sympathetic nerve fibers 
penetrate primary and secondary lymphoid organs (Bulloch and Pomerantz, 1984; Felten 
et al., 1987a) and closely appose CD4+ TH cells residing within the periarteriolar lymphoid 
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sheath (Felten et al., 1987a; Felten and Olschowka, 1987), and the concentration of NE in 
these tissues is much higher than in blood (Felten et al., 1987b). In addition, 
hematopoietic cells express ARs on their surfaces (Bishopric et al., 1980), lymphocytes 
express both ARs and DA receptors (Sanders et al., 2001), NE regulates all aspects of 
immune function through α- and/or β-AR stimulation both in vitro and in vivo (Madden, 
2001). More recently, we reported that β-AR agonist isoproterenol, but not α-AR agonists, 
could decrease splenocyte proliferation as well as IL-2 production at both protein and 
mRNA levels in vitro, which indicating NE modulates lymphocyte proliferation and 
cytokine production via β-ARs (Xie et al., 2002). In light of these findings, peripheral NE 
plays a physiological role in regulation of immune response. Depending on the fact that 
catecholamines and their metabolites are present in lymphocytes, Bergquist et al. (1994) 
proposed that catecholamines could regulate lymphocyte function via an autocrine or 
paracrine loop. Moreover, DA significantly modulates the proliferative capacity of murine 
and human lymphocytes in vitro and in vivo (Tsao et al., 1997; Saha et al., 2002). In the 
present investigation, we observed a reduction of peripheral lymphocyte proliferation and 
splenocyte cytokine production at both protein (IL-2 and IFN-γ) and mRNA (IL-2) levels 
as well as a transient but significant reduction in splenic NE and EPI contents following 
central catecholamine depletion by i.c.v. 6-OHDA injection. Token together, we suggest 
that peripheral SNS plays a role in the modulation of central catecholaminergic system on 
peripheral cellular immune functions. 
 
Although no changes have been reported in cardiac concentrations of catecholamines 
two days after the central 6-OHDA treatment (Cross et al., 1986), this does not rule out 
the possibility that catecholaminergic output in other peripheral tissues changes after i.c.v. 
6-OHDA injection. Indeed, we found a significant decrease in splenic catecholamine 
concentrations four days after the injection, but not two or seven days after the injection, 
supporting our hypothesis that central catecholamine depletion affects peripheral 
sympathetic output. In addition, Deng and colleaques (1983) reported that four weeks 
after i.c.v. 6-OHDA treatment, the contents of NE and EPI in the brain tissues as well as 
in the heart, in the aorta and in plasma were reduced in rats, suggesting that the 
overactivity of peripheral sympatho-adrenal system is dependent on the central 
catecholaminergic neurons. A decrease of endogenous DA in thymus and spleen one day 
after central DA depletion with MPTP in mice was observed as well (Tsao et al., 1997). 
Therefore, it is likely that central catecholamine depletion affects peripheral 
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catecholamine output from sympathetic nerve fibers and the changes of these 
neurotransmitters induce the observed immunosuppressive effects. Our hypothesis is also 
in line with Teunis et al. (2002) who suggest central dopaminergic activity directly and/or 
indirectly controls peripheral processes that are under control of peripheral DA as well. 
Since chemical sympathectomy by peripheral 6-OHDA administration has been well 
established (Madden, 2001), it might be of particular interest for us to test the effects of 
central catecholamine depletion on peripheral immune response in the absence of SNS 
tone to further confirm our hypothesis in further studies. 
 
However, it is also important to realize that the effects of central catecholamine 
depletion are not only limited to SNS and the immune system, but also extended to other 
systems that could interact with both catecholaminergic and immune systems. 
 
First of all, it is well known that several hormones exert their influence on immune 
system. This is primarily mediated through the hormonal receptors present on the surface 
or cytoplasm of different effector cells of the immune system (Bost, 1988; Weigent and 
Blalock, 1987). Central catecholamines are known to affect the activity of HPA axis, 
especially the release and synthesis of several anterior pituitary hormones including 
ACTH, GH, gonadotropin, prolactin and thyroid-stimulating hormone (TSH) (Müller & 
Nisticò, 1989b). Several reports which indicate a significant influence of these anterior 
pituitary hormones on the immune system are available now (Ader et al., 1990). It is also 
widely known that ACTH stimulates the synthesis and release of the glucocorticoids (e.g. 
cortisol and corticosterone) by the cortex of the adrenal glands, which in turn modulates 
immune functions. The facts that rats with a hyperreactive dopaminergic system, who 
share several characteristics with patients who suffer from schizophrenia, show a large 
and long-lasting endocrine response to stressors in terms of release of ACTH and 
corticosteroids (Rots et al., 1996), that hypophysectomy abrogates the immunomodulatory 
effects of intracisternal 6-OHDA injection in mice (Cross et al., 1987), and that basal 
serum corticosterone level is increased for at least 15 days after selective unilateral DA 
depletion in the striatum by 6-OHDA in mice (Filipov et al., 2002), suggest 
pituitary/adrenocortical hormones play a role in the immunomodulatory effects of central 
catecholamine system. Interestingly, MPTP-treated mice have increased basal serum 
corticosterone one week after MPTP injection, a period of time when MPTP-induced 
striatal DA depletion is maximal, but not earlier (Kaku et al., 1999). In addition, the 
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hypothalamus, which regulates pituitary hormone secretion and is affected in PD patients, 
also influences and is influenced by the striatum directly through hypothalamic-striatal 
projections (Sandyk et al., 1987). Moreover, a direct interaction between corticotropin 
releasing factor (CRF) and dopaminergic systems occurs in the striatum, and that 
interaction is altered in animals administered with 6-OHDA (Voilokova et al., 1999). 
Therefore, it is also possible that central catecholamines affect the peripheral immune 
functions through the activity of HPA axis. Assessment of HPA activity should be 
performed in our further investigation as well. 
 
Furthermore, altered central catecholamine levels may also affect the synthesis and 
release of other neurochemicals which are immunomodulatory in nature. For example, 
enkephalins exert immunomodulating activity in vitro and in vivo and constitute important 
components of the neural-endocrine-immune network (Plotnikoff and Miller, 1983; 
Janković and Marić, 1990). Dopaminergic neurons that project to the striatum from the 
substantia nigra are thought to modulate methionine-enkephalin (Met-Enk) metabolism in 
the striatum. Gudehithlu et al. (1991) reported that the Met-Enk-like immunoreactivity 
and preproenkephalin mRNA content in the striatum increased due to central DA 
depletion after MPTP treatment in mice. Intracerebroventricular injections of rats with 
Met-Enk induce reduction in several immune variables like antibody production, 
development of DTH and number of CD4+ TH cells (Janković and Marić, 1990). Met-Enk 
can also stimulate HPA axis which, in turn, stimulates the cells of adrenal cortex to secrete 
corticosterone in circulation and thereby affecting the functional activities of circulating 
lymphocytes (Iyengar et al., 1987). Moreover, the level of somatostatin, known to have 
considerable influence on immune response, is also altered for a few days after MPTP 
treatment in mice (Stanisz et al., 1986; Asanuma et al., 1990). The role of these 
neurochemicals in the immunomodulatory effects of central catecholamine depletion also 
needs further investigations. 
 
Although Bas et al. (2001) reported that PD patients had a decrease in the number of 
CD4+ TH cells and B cells, and a rise in activated, CD4+CD25+ T cells in their peripheral 
blood, the influence of central catecholamine depletion on lymphocyte distribution in 
primary and secondary lymphoid organs remains unclear (Bas et al., 2001; Bieganowska 
et al., 1996; Renoux et al., 1989). Since peripheral catecholamines can regulate 
lymphocyte trafficking as well as its entry, retention and release from lymphoid organs 
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(Madden, 2001), and central catecholamine depletion alters catecholamine output from 
sympathetic nerve fibres as reported by Deng et al. (1983) and in the present 
investigation, it might also be interesting for us to investigate the effects of central 
catecholamine depletion on lymphocyte circulation in peripheral blood and redistribution 
among the lymphoid organs in our future studies. 
 
Data regarding the effects of central catecholamine depletion on peripheral immune 
response are still unclear (Cross et al., 1986; Renoux et al., 1989; Neveu et al., 1992; 
Deleplanque et al., 1992; Bieganowska et al., 1993; Deleplanque et al., 1994; Devoino et 
al., 1997). Observed discrepancies may be a result of differences in experimental design, 
specificity of the neurotoxin (6-OHDA vs. MPTP), central catecholamines depleted (NE 
and DA vs. DA along), species used (mice vs. rats), immunological variables measured 
(humoral vs. cellular), or immune compartments being investigated (spleen, peripheral 
blood or lymph nodes). In addition, the time point of the assay after central catecholamine 
depletion and the approach used to assess immunity (in vitro vs. in vivo) are likely to be 
critical (Alaniz et al., 1999; Filipov et al., 2002; Teunis et al., 2002). Therefore, it will be 
necessery to consider these methodological aspects carefully in designing future 
experiments. 
 
Regardless of the mechanisms involved, the suppression of peripheral cellular immune 
functions including decreased lymphocyte proliferation in spleen and peripheral blood, 
reduced splenocyte cytokine production at both protein (IL-2 and IFN-γ) and mRNA (IL-
2) levels after central catecholamine depletion by i.c.v. 6-OHDA treatment, which is 
crucial to interpretation of studies concerning neural-endocrine-immune communications, 
was found in the present study. Therefore, the present investigation makes further 
contribution to understanding the regulation of systematic depletion of central 
catecholamines on peripheral cellular immune functions in rats. Future work will involve 
determining the influence of central catecholamine depletion on peripheral cellular as well 
as humoral immune responses in the absence of SNS tone and the relationships among 
central catecholamine depletion, alterations of SNS, of HPA axis, and of other 
neurotransmitter systems in CNS, and peripheral immunological changes. 
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5. Abbreviations 
 
ACTH adrenocorticotropic hormone 
AIDS acquired immunodeficiency syndrome 
ANOVA analysis of variance 
AR(s) adrenergic receptor(s) 
BBB blood-brain barrier 
BSA bovine serum albumin 
CFP culture filtrate proteins 
CNS central nervous system 
Con A concanavalin A 
CRF corticotropin releasing factor 
CTLs cytotoxic T lymphocytes 
DA dopamine 
DBH dopamine beta-hydroxylase 
DDC diethyldithiocarbamate 
DTH delayed-type hypersensitivity 
ELISA enzyme-linked immunosorbent assay 
EPI epinephrine 
FCS fetal calf serum  
GBR-12935 GBR-12935 dihydrochloride 
GH growth hormone 
GTC guanidinium thiocyanate 
HPA hypothalamic-pituitary-adrenocortical 
HPLC high-performance liquid chromatography 
i.c.v. intracerebroventricular 
IFN interferon 
IL interleukin 
i.p. intraperitoneal 
KLH keyhole limpet hemocyanin 
LM Listeria monocytogenes 
LPS lipopolysaccharide 
MAO-B monoamine oxidase-B 
Met-Enk methionine-enkephalin 
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MLC mixed lymphocyte culture 
MPDP 1-methyl-4-phenyl-2,3-dehydropyridine 
MPP+ 1-methyl-4-phenylpyridine 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MT Mycobacterium tuberculosis 
NE norepinephrine 
NK natural killer 
PBS phosphate buffered saline 
PD Parkinson’s disease 
PFC plaque-forming cells  
PHA phytohaemagglutinin 
PNMT phenylethanolamine-N-methyltransferase 
PWM pokeweed mitogen 
PCR polymerase chain reaction 
RFC rosette-forming cell 
RT reverse transcription 
6-OHDA 6-hydroxydopamine 
SNS sympathetic nervous system 
SPF specific pathogen-free 
SRBC sheep red blood cells 
TH T-helper 
Th1 T-helper-1 
Th2 T-helper-2 
TMB tetramethylbenzidine 
TNF tumor necrosis factor 
TNP trinitrophenyl 
TSH thyroid-stimulating hormone 
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6. Summary 
 
Evidence demonstrating that immune response is under the control of central nervous 
system has been accumulated during the past two decades. Central catecholamines have 
been proved to play a pivotal role in modulation of humoral and cellular immunity both in 
vitro and in vivo. However, the modulation of central catecholamine depletion on 
peripheral cellular immune response remains somewhat unclear. Therefore, we designed a 
set of experiments to analyse the influence of central catecholamine depletion by i.c.v. 6-
OHDA injection on peripheral cellular immune functions. Two, four and seven days after 
the injection in rats, they were sacrificed and spleen and blood samples were collected to 
measure the lymphocyte proliferation, cytokine production and IL-2 mRNA expression. 
Brain and spleen samples were obtained for catecholamine determination as well. Our 
data demonstrate that two, four and seven days after i.c.v. 6-OHDA treatment, dopamine, 
norepinephrine and epinephrine levels in the hypothalamus and in the cortex are 
significantly reduced. Additionally, norepinephrine and epinephrine concentrations in the 
spleen are significantly decreased four days after the injection. In contrast, the serotonin 
levels in the brain and in the spleen are not changed seven days after the central 6-OHDA 
treatment. More importantly, Con A-induced lymphocyte proliferation and splenocyte 
cytokine production at both protein (IL-2 and IFN-γ) and mRNA (IL-2) levels are 
significantly reduced seven days after i.c.v. 6-OHDA injection. These results confirm the 
important role of central catecholamines in modulating peripheral cellular immune 
response. Although the precise mechanism of how central catecholamine depletion alters 
peripheral cellular immunity is still not clear, the fact that a significant reduction in 
splenic catecholamine contents is observed four days after i.c.v. 6-OHDA treatment 
suggests that peripheral sympathetic nervous system plays a role in these effects. 
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